Newsletter | December 15, 2021

12.15.21 -- Cell & Gene Top 10 Of 2021

 

Dear Cell & Gene readers, 


What a year it's been in the cell and gene sector! Throughout 2021, Cell & Gene delivered impactful editorial on R&D, supply chain and logistics, the long, regulated road to commercialization, and everything in between. We launched Cell & Gene: The Podcast featuring some of the sector's best and brightest leaders, and we've continued our Cell & Gene Live webinar series. In 2022 (and beyond), we're excited to continue our mission of bringing you the most timely insight to help you better perform your role.

 

For your convenience, we’ve compiled a list of this year’s Top 10 most-read “Guest” and “From the Editor” columns, “Industry Insights,” and “Products and Services.” Whether they’re new to you, or to review, be sure to give these articles a read.

 

From all of us at Cell & Gene, we wish you and yours a safe and healthy 2022.

 

Erin Harris, editor in chief
Follow me on Twitter

Top 10 Featured Editorial
  1. An Analysis Of The Gene Therapy Viral Vector Landscape
  2. Driving Down Costs of Autologous Cell Therapy Manufacturing
  3. The Next Decade In Gene Therapy Innovation — 6 Critical Questions (And Answers)
  4. Medicare Braces For Expanded Use Of High-Cost CAR T-Cell Therapy
  5. Inside BioCardia’s CardiAMP Cell Therapy
  6. Why Elevating Responsibility To The C-suite Can Help Avoid Manufacturing Missteps
  7. Cell & Gene Therapy Bioprocessing: Demand For Better Process Control, Expertise & CMOs
  8. Cell & Gene Therapies For Parkinson’s Disease
Top 10 Industry Insights
  1. Cell Therapy Facility Design Synopsis: Horizontal vs. Vertical
  2. Viral Vector Scale-Up: How Can We Bridge The Technology Gaps?
Top 10 Products And Services
  1. Your Cell And Gene Therapy Journey: From Discovery To Commercialization
    Thermo Fisher Scientific – Cell & Gene Therapy
  2. Bigfoot Cell Sorter
    Thermo Fisher Scientific
  3. ONE Lentiviral Vector Production System
    Thermo Fisher Scientific Bioproduction